Michael Tuscan

Partner
Full contact info

Experience

EyeBiotech Limited Announces $130 Million Series A

November 14, 2023

Cooley advised EyeBiotech Limited, a privately held, clinical-stage ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, on the close of an extension to its Series A financing, bringing the total raised to date to $130 million.

Related contacts

Tom Goodman
Partner, London
Michael Tuscan
Partner, Washington, DC
Christian Plaza
Partner, Reston
Nicola Maguire
Partner, London
Karen Tsai
Special Counsel, Washington, DC
Annie Froehlich
Partner, Washington, DC
Bonnie Weiss McLeod
Of Counsel, Washington, DC
Kerry Corrigan
Associate, London
Ellen Dewhurst
Associate, London

Related Practices & Industries

MapLight Therapeutics Closes Oversubscribed $225 Million Series C

November 3, 2023

Cooley advised MapLight Therapeutics, a clinical-stage biopharmaceutical company, on its oversubscribed $225 million Series C financing.

Read more

Related contacts

Christian Plaza
Partner, Reston
Matthew Schwee
Partner, Reston
David Brinton
Associate, Washington, DC
Michael Tuscan
Partner, Washington, DC
Jim Fulton
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Jason Valentine
Associate, Washington, DC
Cortney Smith
Senior Paralegal, Reston
Jeffery Wyzykowski
Patent Agent, Washington, DC
Dou Yeon Youn
Patent Agent, New York
Zhipeng Zheng
Patent Agent, Washington, DC

Related Practices & Industries

Sixth Street Invests in Blueprint Medicines

July 7, 2022

Cooley advised global investment firm Sixth Street on its strategic investment in Blueprint Medicines, a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Lawyers Mischi a Marca, Matt Browne, Matt Scarano, Addison Pierce, Matt Kong and Nick Neuteufel led the Cooley team advising Sixth Street. 

Read more

Related contacts

Mischi a Marca
Partner, San Francisco
Matt Browne
Partner, San Diego
Matthew S. Scarano
Associate, San Diego
Addison Pierce
Associate, Chicago
Matt Kong
Associate, San Francisco
Michael Tuscan
Partner, Washington, DC
Jon Cousin
Partner, Washington, DC
Tanya Heare-Rowlands
Special Counsel, London
Jeffery Wyzykowski
Patent Agent, Washington, DC
Matthew Scheideman
Patent Agent, Washington, DC
Charity Williams
Partner, San Diego
Freddy Yip
Associate, Hong Kong
Zack Gong
Associate, Shanghai
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Jennifer Shanley
Special Counsel, New York
Elizabeth Anne Wright
Partner, Brussels
Aaron Pomeroy
Partner, Colorado
Michael Klein
Partner, New York
Paul Springer
Associate, New York
Megan Browdie
Partner, Washington, DC
Howard Morse
Partner, Washington, DC

Related Practices & Industries

Forbius Agrees to Sell to Bristol Myers Squibb

August 25, 2020

Cooley advised Forbius – a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases – on its agreement to sell to Bristol Myers Squibb. Barbara Borden, Marya Postner and Rowook Park led the Cooley team advising Forbius. 

Read more

Related contacts

Rowook Park
Partner, San Diego
Barbara Borden
Partner, San Diego
Rajdeep Roger Bains
Associate, San Diego
David Dalton
Associate, Los Angeles Santa Monica
Xander Lee
Partner, Los Angeles Santa Monica
Lindsey O'Crump
Associate, Washington, DC
Marya Postner
Partner, Palo Alto
Michael Tuscan
Partner, Washington, DC
Aaron Pomeroy
Partner, Colorado
Barbara Mirza
Partner, Los Angeles Santa Monica
Ross Eberly
Partner, Los Angeles Santa Monica
Dionne A. Thomas
Associate, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Jane Adams
Partner, San Diego
Jeffery Wyzykowski
Patent Agent, Washington, DC
Phil Mitchell
Partner, New York
Steve Cuss
Associate, London
Tanya Heare-Rowlands
Special Counsel, London

Related Practices & Industries

Iconic Therapeutics Series C Financing

January 13, 2016

Cooley advised Iconic Therapeutics on the closing of its $40 million Series C financing. The round included new investors HBM Healthcare Investments, Cormorant Asset Management and Osage University Partners. All of Iconic's existing investors, including MPM Capital, H.I.G. Capital and Lundbeck fund Ventures, participated in the round.

According to Iconic, proceeds from the financing will be used to advance development of lead molecule ICON-1 in retinal diseases as well as begin clinical trials in ocular melanoma, Iconic's first oncology indication.

Iconic is a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer.

The team advising Iconic included Mark Weeks, Anita Vasudevan, Daniel Elefant, Mike Tuscan and Marya Postner.

Related contacts

Mark Weeks
Partner, Palo Alto
Anita Vasudevan
Special Counsel, Palo Alto
Michael Tuscan
Partner, Washington, DC
Marya Postner
Partner, Palo Alto

Related Practices & Industries

View more

Rankings & accolades

Best Lawyers in America: Technology Law

Best Lawyers: Leading IP Lawyer

IAM Patent 1000: Top Patent Lawyer

Legal 500: Top Lawyer for Life Sciences and Patent Prosecution

Managing Intellectual Property: IP Star

Who's Who Legal: Top Patent Lawyer